trans-Fatty acid intake and increased risk of advanced prostate cancer: Modification by RNASEL R462Q variant

Carcinogenesis

Volumn 28, Issue 6, 2007, Pages 1232-1236

  Liu, Xin ^a,d   Schumacher, Fredrick R ^b   Plummer, Sarah J ^c   Jorgenson, Eric ^a   Casey, Graham ^c   Witte, John S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; RIBONUCLEASE L;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CALORIC INTAKE; CANCER RISK; CASE CONTROL STUDY; CAUCASIAN; CONFIDENCE INTERVAL; CONTROLLED STUDY; FAT INTAKE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; STATISTICAL SIGNIFICANCE;

AGED; AMINO ACID SUBSTITUTION; ARGININE; CASE-CONTROL STUDIES; DIETARY FATS, UNSATURATED; ENDORIBONUCLEASES; GLUTAMINE; HUMANS; MALE; PROSTATIC NEOPLASMS; RISK FACTORS; TRANS FATTY ACIDS;

EID: 34447328433     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgm002     Document Type: Article

References (53)

1. Chardigny,J.M. et al. (1996) Identification of novel trans isomers of 20:5N-3 in liver lipids of rats fed a heated oil. Lipids, 31 165-168.
2. van Poppel,G. (1998) Intake of trans fatty acids in western Europe: The TRANSFAIR study. Lancet, 351, 1099.
3. Clifton,P.M. et al. (2004) Trans fatty acids in adipose tissue and the food supply are associated with myocardial infarction. J. Nutr. 134, 874-879.
4. Lemaitre,R.N. et al. (2002) Cell membrane trans-fatty acids and the risk of primary cardiac arrest. Circulation, 105, 697-701.
5. Willett,W.C. (2006) Trans fatty acids and cardiovascular disease-epidemiological data. Atheroscler. Suppl., 7, 5-8.
6. Baer,D.J. et al. (2004) Dietary fatty acids affect plasma markers of inflammation in healthy men fed controlled diets: A randomized crossover study. Am. J. Clin. Nutr., 79, 969-973.
7. Han,S.N. et al. (2002) Effect of hydrogenated and saturated, relative to polyunsaturated, fat on immune and inflammatory responses of adults with moderate hypercholesterolemia. J. Lipid Res., 43 445-452.
8. Lopez-Garcia,E. et al. (2005) Consumption of trans fatty acids is related to plasma biomarkers of inflammation and endothelial dysfunction. J. Nutr., 135, 562-566.
9. Mozaffarian,D. et al. (2004) Dietary intake of trans fatty acids and systemic inflammation in women. Am. J. Clin. Nutr., 79, 606-612.
10. Mozaffarian,D. et al. (2004) trans Fatty acids and systemic inflammation in heart failure. Am. J. Clin. Nutr., 80, 1521-1525.
11. Bakker,N. et al. (1997) Adipose fatty acids and cancers of the breast, prostate and colon: An ecological study. EURAMIC study group. Int. J. Cancer, 72, 587-591.
12. Kohlmeier,L. (1997) Biomarkers of fatty acid exposure and breast cancer risk. Am. J. Clin. Nutr., 66, 1548S-1556S.
13. Slattery,M.L. et al. (2001) Trans-fatty acids and colon cancer. Nutr Cancer, 39, 170-175.
14. Slattery,M.L. et al. (2002) Diet activity, and lifestyle associations with p53 mutations in colon tumors. Cancer Epidemiol. Biomarkers Prev., 11, 541-548.
15. King,I.B. et al. (2005) Serum trans-fatty acids are associated with risk of prostate cancer in beta-carotene and retinol efficacy trial. Cancer Epidemiol. Biomarkers Prev., 14, 988-992.
16. Hodge,A.M. et al. (2004) Foods, nutrients and prostate cancer. Cancer Causes Control, 15, 11-20.
17. Schuurman,A.G. et al. (1999) Association of energy and fat intake with prostate carcinoma risk: Results from The Netherlands cohort study. Cancer, 86, 1019-1027.
18. Casey,G. et al. (2002) RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat. Genet., 32, 581-583.
19. Wang,L. et al. (2002) Analysis of the RNASEL gene in familial and sporadic prostate cancer. Am. J. Hum. Genet., 71, 116-123.
20. Maier,C. et al. (2005) Mutation screening and association study of RNASEL as a prostate cancer susceptibility gene. Br J. Cancer, 92, 1159-1164.
21. Nakazato,H. et al. (2003) Role of genetic polymorphisms of the RNASEL gene on familial prostate cancer risk in a Japanese population. Br J. Cancer, 89, 691-696.
22. Noonan-Wheeler,F.C. et al. (2006) Association of hereditary prostate cancer gene polymorphic variants with sporadic aggressive prostate carcinoma. Prostate, 66, 49-56.
23. Rennert,H. et al. (2002) A novel founder mutation in the RNASEL gene, 471delAAAG, is associated with prostate cancer in Ashkenazi Jews. Am. J. Hum. Genet., 71, 981-984.
24. Rennert,H. et al. (2005) Association of susceptibility alleles in ELAC2/HPC2, RNASEL/HPC1, and MSR1 with prostate cancer severity in European American and African American men. Cancer Epidemiol. Biomarkers Prev., 14, 949-957.
25. Rokman,A. et al. (2002) Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer. Am. J. Hum. Genet., 70, 1299-1304.
26. Wiklund,F. et al. (2004) Genetic analysis of the RNASEL gene in hereditary, familial, and sporadic prostate cancer. Clin. Cancer Res. 10, 7150-7156.
27. Lindmark,F. et al. (2004) Analysis of the macrophage scavenger receptor 1 gene in Swedish hereditary and sporadic prostate cancer. Prostate, 59, 132-140.
28. Miller,D.C. et al. (2003) Germ-line mutations of the macrophage scavenger receptor 1 gene: Association with prostate cancer risk in African-American men. Cancer Res., 63, 3486-3489.
29. Seppala,E.H. et al. (2003) Germ-line alterations in MSR1 gene and prostate cancer risk. Clin. Cancer Res., 9, 5252-5256.
30. Sun,J. et al. (2006) Meta-analysis of association of rare mutations and common sequence variants in the MSR1 gene and prostate cancer risk. Prostate, 66, 728-737.
31. Panguluri,R.C. et al. (2004) COX-2 gene promoter haplotypes and prostate cancer risk. Carcinogenesis, 25, 961-966.
32. Shahedi,K. et al. (2006) Genetic variation in the COX-2 gene and the association with prostate cancer risk. Int. J. Cancer, 119 668-672.
33. Oh,B.R. et al. (2000) Frequent genotype changes at -308, and 488 regions of the tumor necrosis factor-alpha (TNF-alpha) gene in patients with prostate cancer. J. Urol., 163, 1584-1587.
34. Wu,H.C. et al. (2004) p53 gene codon 72 polymorphism but not tumor necrosis factor-alpha gene is associated with prostate cancer. Urol. Int., 73, 41-46.
35. Chen Y.C. et al. (2005) Sequence variants of Toll-like receptor 4 and susceptibility to prostate cancer. Cancer Res., 65, 11771-11778.
36. Sun,J. et al. (2005) Sequence variants in Toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk. J. Natl Cancer Inst., 97, 525-532.
37. Xu,J. et al. (2005) The interaction of four genes in the inflammation pathway significantly predicts prostate cancer risk. Cancer Epidemiol. Biomarkers Prev., 14, 2563-2568.
38. Zheng,S.L. et al. (2004) Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: Results from the cancer prostate in Sweden study. Cancer Res., 64, 2918-2922.
39. Carpten,J. et al. (2002) Germline mutations in the ribonuclease L gene in families showing linkage with HPC1 Nat. Genet., 30, 181-184.
40. Castelli,J.C. et al. (1998) The role of 2′-5′ oligoadenylate-activated ribonuclease L in apoptosis. Cell Death Differ., 5, 313-320.
41. Hassel,B.A. et al. (1993) A dominant negative mutant of 2-5A-dependent RNase suppresses antiproliferative and antiviral effects of interferon. EMBO J., 12, 3297-3304.
42. Zhou,A. et al. (1997) Interferon action and apoptosis are defective in mice devoid of 2′, 5′-oligoadenylate-dependent RNase L. EMBO J., 16, 6355-6363.
43. Xiang,Y. et al. (2003) Effects of RNase L mutations associated with prostate cancer on apoptosis induced by 2′, 5′-oligoadenylates. Cancer Res., 63, 6795-6801.
44. Sobin,L.H. et al. (1997) TNM Classification of Malignant Tumors Wiley-Liss, New York.
45. Liu,X et al. (2006) Nonsteroidal anti-inflammatory drugs and decreased risk of advanced prostate cancer: Modification by lymphotoxin alpha. Am. J. Epidemiol., 15, 984-989.
46. Patterson,R.E. et al. (1999) Measurement characteristics of the Women's Health Initiative food frequency questionnaire. Ann. Epidemiol., 9, 178-187.
47. Satia-Abouta,J. et al. (2003) Associations of total energy and macronutrients with colon cancer risk in African Americans and Whites: results from the North Carolina colon cancer study. Am J. Epidemiol. 158, 951-962.
48. Willett,W. (1990) Implications of total energy intake for epidemiologic analyses. In Willett, W. (ed.) Nutritional Epidemiology. Oxford University Press, New York, pp. 245-271.
49. Innis,S.M. (2006) Trans fatty intakes during pregnancy, infancy and early childhood. Atheroscler Suppl., 7, 17-20.
50. Semma,M. (2002) Trans fatty acids: Properties, benefits and risks. J. Health Sci., 48, 7-13.
51. Hulshof,K.F. et al. (1999) Intake of fatty acids in western Europe with emphasis on trans fatty acids: The TRANSFAIR study. Eur. J. Clin. Nutr., 53, 143-157.
52. Ip,C. (1997) Review of the effects of trans fatty acids, oleic acid, n-3 polyunsaturated fatty acids, and conjugated linoleic acid on mammary carcinogenesis in animals. Am. J. Clin. Nutr., 66, 1523S-1529S.
53. Urisman,A. et al. (2006) Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. PLoS Pathog., 2, e25.